JERSEY, Channel Islands, May 31, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2017 Global Healthcare Conference on Wednesday, June
Initial MosaiQ manufacturing system commissioned and validated First "commercially ready" MosaiQ Instrument delivered to Quotient Internal validation of MosaiQ underway , with EU field trials expected in 3QCY17 Fourth quarter revenues of $5.5 million and Product sales of $4.7 million, exceeding
JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at
JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal year ended March 31, 2017 will be released after market close on Monday, May 22, 2017.
JERSEY, Channel Islands, April 10, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the closing of its underwritten public offering of 8,050,000 of its ordinary shares at a price to the public of $6.00 per share, which includes the
JERSEY, Channel Islands, April 05, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the pricing of an underwritten public offering of 7,000,000 of its ordinary shares at a price to the public of $6.00 per share.
JERSEY, Channel Islands, April 04, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares. Jefferies LLC is acting as sole book-running manager and BTIG, LLC
Antibody Detection — enhanced detection versus predicate technologies Manufacturing of Microarrays for European field trials planned to commence in early April MosaiQ ™ instrument development completed and formal validation has commenced Completion of European field trials expected in
Products are rare antisera blood typing reagents developed and manufactured by Quotient U.S. commercialization of these products will extend the range and method of reagents available in the market for antigen phenotyping Equivalent products are already approved and commercialized outside of the
JERSEY, Channel Islands, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen and Company 37 th Annual Health Care Conference on
